Questions and answers: What can be said by diagnostic imaging in neuroendocrine tumors?

V. Cuccurullo, A. Faggiano, M. Scialpi, G. L. Cascini, A. Piunno, O. Catalano, A. Colao, L. Mansi

Research output: Contribution to journalArticlepeer-review


The neuroendocrine tumors (NET) of the gastro-entero-pancreatic area (GEP) represent a heterogeneous group of malignancies from the histologic, clinico-laboratoristic (functioning and non-functioning variants), and therapeutic point of view. It is an issue becoming more frequent for the diagnostic imager, being radiologist as well as nuclear physician. Imaging (together with biopsy) plays a key role in the diagnostic assessment and staging (including grading and prognostic definition), in evaluating response to treatment, and in follow-up of GEP-NET. Multislice computed tomography (MSCT), octreoscan and PET-CT are the most widely diffuse and accurate imaging modalities employed in this setting. Other methods, such as Magnetic Resonance and Endoscopic Ultrasound, may also play a significant role.

Original languageEnglish
Pages (from-to)367-377
Number of pages11
JournalMinerva Endocrinologica
Issue number4
Publication statusPublished - Dec 2012


  • Diagnostic imaging
  • Neuroendocrine tumors
  • Nuclear medicine
  • Radiology

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrinology

Fingerprint Dive into the research topics of 'Questions and answers: What can be said by diagnostic imaging in neuroendocrine tumors?'. Together they form a unique fingerprint.

Cite this